Pharmaceuticals 14 December 2025

Johnson & Johnson Stock (JNJ) News Today: RBC Raises Target to $240 as FDA Actions and Talc Verdict Shape the 2026 Outlook

CAs of Wednesday, December 17, 2025, Johnson & Johnson is back in focus for investors looking for a “defensive” large-cap healthcare stock—while also weighing two forces that can move JNJ shares quickly: drug pipeline catalysts and talc litigation headlines.

17 December 2025

NYSE:JNJ·Pharmaceuticals

GSK plc (GSK) news: FDA approves twice‑yearly asthma biologic Exdensur on Dec. 17, 2025

GSK plc announced today that the FDA approved Exdensur for severe eosinophilic asthma in patients 12+. Here’s what it means for GSK’s respiratory pipeline, competition, and shareholders on 17.12.2025.

17 December 2025

Healthcare News·LSE:GSK·NYSE:GSK·Pharmaceuticals

Structure Therapeutics (GPCR) Stock: Why Shares Are Sliding on Dec. 16, 2025 After Breakout Obesity Pill Data and a $747.5M Offering

Structure Therapeutics Inc. is having a classic biotech moment on Tuesday, December 16, 2025: big catalyst, big financing, and now big volatility. Shares were down about 6% in Tuesday trading, recently around $60.73, after swinging between roughly $58.95 and $65.69 intraday.

16 December 2025

Biotechnology·NASDAQ:GPCR·Pharmaceuticals·Stock Market

Arrowhead Pharmaceuticals (ARWR) Stock Drops on Dec. 16, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching

Arrowhead Pharmaceuticals, Inc. is seeing a sharp pullback in Tuesday trading, with shares recently changing hands around $62—down roughly 9% from the prior close—after hitting an intraday low near $59.76.

16 December 2025

NASDAQ:ARWR·Pharmaceuticals·Stock Market

Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus

Pfizer Inc. shares fell sharply in U.S. trading on Tuesday, December 16, 2025, as investors weighed the drugmaker’s first look at full-year 2026 guidance, an updated 2025 revenue outlook, and fresh commentary on cost savings and capital allocation. By late morning ET, Pfizer stock was trading around $25, down roughly 5% on the day after swinging between the mid-$26s and just under $25.

16 December 2025

Earnings Reports·NYSE:PFE·Pfizer·Pharmaceuticals·Stock Market

Johnson & Johnson Stock (JNJ) Today: FDA Priority Voucher, Talc Verdict, Earnings Date and 2026 Growth Outlook

December 16, 2025 — Johnson & Johnson stock is trading lower on Tuesday after pushing to fresh highs earlier this week, as investors weigh a mix of pipeline momentum, legal headlines, and an approaching earnings update that could clarify the company’s 2026 trajectory. StockAnalysis+1

16 December 2025

Earnings Reports·NYSE:JNJ·Pharmaceuticals·Stock Market

Eli Lilly Stock (LLY) News, Forecasts and Outlook — Updated Dec. 16, 2025

Eli Lilly and Company stock remains one of the market’s most closely watched healthcare names as 2025 winds down—powered by blockbuster demand for obesity and diabetes medicines, and increasingly driven by what comes next: faster, deeper weight loss therapies, an oral GLP-1 pipeline, and a manufacturing expansion designed to keep up with demand.

16 December 2025

NYSE:LLY·Pharmaceuticals·Stock Market

Pfizer Forecasts Flat 2026 Sales and Lower Profit as COVID Demand Falls; PFE Dividend Remains $0.43

Pfizer’s latest outlook is setting the tone for how investors may view the drugmaker’s post-pandemic transition in 2026: steady underlying growth ambitions, but a near-term financial “air pocket” as COVID-19 revenue continues to shrink and several products face patent and exclusivity headwinds.

16 December 2025

Dividends·NYSE:PFE·Pharmaceuticals·Stock Market

Terns Pharmaceuticals (TERN) Stock Today: Latest News, Analyst Forecasts, and What to Watch (December 16, 2025)

Terns Pharmaceuticals, Inc. is still living inside one of the more dramatic biotech story arcs of 2025: eye-popping clinical data, followed immediately by a massive equity raise, followed by a flurry of analyst price-target resets.

16 December 2025

NASDAQ:TERN·Pharmaceuticals·Stock Market

Pfizer Stock (PFE) Today, Dec. 16, 2025: 2026 Guidance Call Looms as Analysts Weigh Dividend, Deal Flow, and Policy Risks

Pfizer Inc. heads into Tuesday, December 16, 2025 with a familiar “big pharma” cocktail of catalysts: an imminent guidance event, a high dividend yield, fresh dealmaking in hot therapeutic areas, and a regulatory backdrop that can flip sentiment faster than a lab centrifuge.

16 December 2025

Dividends·NYSE:PFE·Pharmaceuticals·Stock Market

Nektar Therapeutics Stock (NKTR) Surges Into a Major Catalyst: What to Know Ahead of Today’s REZOLVE-AA Data

Shares climbed in pre-market and overnight trading as investors positioned for topline results from the 36-week induction period of Nektar’s Phase 2b REZOLVE-AA study in severe-to-very-severe alopecia areata, featuring its lead investigational candidate rezpegaldesleukin. The company scheduled an investor call and webcast for 8:00 a.m. ET, and said the topline results would be released in a morning press release before the webcast. PR Newswire+1

16 December 2025

NASDAQ:NKTR·Pharmaceuticals·Stock Market

GSK plc Stock News Today (16.12.2025): Exdensur UK Approval Puts GSK Shares in Focus as FDA Decision Looms

December 16, 2025 — GSK plc stock is firmly on investors’ radar today after a cluster of late-year regulatory catalysts across respiratory, vaccines, and infectious diseases — the kind of headline flow that can reshape sentiment around a large-cap biopharma even when quarterly earnings are weeks away.

16 December 2025

LSE:GSK·Pharmaceuticals·Stock Market

Merck Stock (MRK) News Today: BofA Raises Target to $120 as Winrevair Expansion and Dividend Date Spotlight 2026 Outlook

December 15, 2025 — Merck & Co., Inc. traded around $99.59 in Monday afternoon action, down about 0.23% on the day, as investors balanced a fresh wave of bullish analyst updates against a busy set of catalysts spanning Winrevair, Keytruda, vaccines, and headline regulatory scrutiny.

15 December 2025

NYSE:MRK·Pharmaceuticals·Stock Market

AbbVie (ABBV) Stock News and Forecasts Today: BofA Cuts Price Target to $233 as Wall Street Debates 2026 Pipeline Catalysts

AbbVie Inc. stock traded higher on Monday, December 15, 2025, as investors balanced fresh analyst commentary with new exclusivity-related headlines tied to one of the company’s neuroscience brands. Shares were recently around $227, up roughly 1.7% on the session.

15 December 2025

NYSE:ABBV·Pharmaceuticals·Stock Market

Johnson & Johnson Stock (JNJ) Today: FDA Fast‑Track Voucher Lifts Oncology Narrative as Talc Verdict Renews Legal Overhang

Johnson & Johnson stock is starting the week at the center of two storylines that often tug the share price in opposite directions: accelerating momentum in oncology and a stubborn, headline‑driven litigation risk.

15 December 2025

NYSE:JNJ·Pharmaceuticals·Stock Market

Catalyst Pharmaceuticals CPRX Stock News, Forecasts and Analyst Outlook for December 15, 2025

December 15, 2025 — Catalyst Pharmaceuticals, Inc. is getting fresh attention on Monday as the company tees up a high-visibility appearance at the J.P. Morgan Healthcare Conference early next year, while traders and analysts continue to debate the stock’s “next leg” after a strong 2025 run in rare-disease commercialization.

15 December 2025

NASDAQ:CPRX·Pharmaceuticals

Eli Lilly Stock (LLY) News Today: Retatrutide Breakthrough, Orforglipron FDA Timeline, and Analyst Forecasts on December 15, 2025

December 15, 2025 — Eli Lilly and Company stock is starting the new week in focus as investors weigh a rapid-fire set of catalysts: a headline-grabbing Phase 3 result for next‑generation obesity drug retatrutide, fresh scrutiny around the FDA review timeline for oral GLP‑1 candidate orforglipron, ongoing capacity expansion in the U.S., and a notable analyst price-target tweak hitting the tape today. MarketBeat+3Reuters+3Reuters+3

15 December 2025

NYSE:LLY·Pharmaceuticals·Stock Market

Sanofi Stock (SAN.PA, SNY) Slides After Tolebrutinib Double Setback: FDA Delay, Trial Miss, and Fresh Analyst Forecasts (Dec. 15, 2025)

Sanofi stock is under pressure on December 15, 2025, after the French drugmaker disclosed two setbacks tied to its experimental multiple sclerosis medicine tolebrutinib—a regulatory delay in the U.S. for one progressive MS form and a failed Phase 3 endpoint in another. The update pushed Sanofi shares down about 4% in Paris trading, as investors recalibrated expectations for one of the company’s closely watched late-stage pipeline assets. Reuters+1

15 December 2025

EPA:SAN.PA·NASDAQ:SNY·Pharmaceuticals·Stock Market

Vertex Pharmaceuticals (VRTX) Stock: What to Know Before the Market Opens on Dec. 15, 2025

Vertex Pharmaceuticals Incorporated heads into the Monday, December 15, 2025 U.S. market open with investors weighing a familiar mix: a dominant cystic fibrosis franchise that funds the story, and a fast-expanding pipeline that’s increasingly driving the debate about what Vertex should be worth next.

15 December 2025

NASDAQ:VRTX·Pharmaceuticals·Stock Market

AbbVie (ABBV) Stock: What to Know Before the US Market Opens on December 15, 2025

AbbVie Inc. heads into the Monday, December 15, 2025 US market open with a familiar “big pharma” setup—steady cash returns, blockbuster execution, and a pipeline that’s increasingly being treated as a source of upside rather than a safety net. Shares last traded around $223.32, slipping modestly at Friday’s close as broader markets softened, but ABBV remains one of the stronger large-cap pharma performers in 2025. MarketWatch

14 December 2025

NYSE:ABBV·Pharmaceuticals·Stock Market

Pharmaceuticals 14 December 2025 - 17 December 2025